Organomegaly in Mali before and after praziquantel treatment. A possible association with Schistosoma haematobium

• Published in: Heliyon Vol. 3; no. 11; p. e00440
• Main Authors: Stecher, Chalotte Willemann, Madsen, Henry, Wilson, Shona, Sacko, Moussa, Wejse, Christian, Keita, Adama D., Landouré, Aly, Traoré, Mamadou S., Kallestrup, Per, Petersen, Eskild, Vennervald, Birgitte
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.11.2017; Elsevier
• Subjects: Infectious disease; Infectious disease
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2017.e00440

Continuous exposure to schistosome-infested water results in acute and chronic morbidity in all ages. We analysed occurence of organomegaly via ultrasonography and investigated a possible additive effect of dual-dose drug administration in 401 Schistosoma haematobium infected individuals from a highly endemic area in Mali. Mean intensity of infection at baseline (22.0 eggs per 10 ml) was reduced to 0.22 eggs per 10 ml 9 weeks after treatment (both treatments combined). Odds of persistent infection among those given dual-dose treatment was 41% of that in people given single dose (b = 0.41; p = 0.05; 95% CI 0.17–1.00), but after two years, 70.7% of the 157 participants, who completed the survey, were re-infected with no significant difference in prevalence and intensity of infection between treatment groups. Resolution of organomegaly occurred in all age groups after treatment. A novel association between Schistosoma haematobium infection and moderate portal vein enlargement was found in 35% (n: 55). Severe portal vein diameter enlargement was found in 3.2%. After two years, moderate hepatomegaly was present in 50.6%, moderate splenomegaly in 45.6% and moderate portal vein diameter enlargement in 19%. A subsequent dose of PZQ did not provide any additional long-term advantages.